Sanofi-aventis, Stanford University Bio-X ink research pact
As per the terms of the pact, both the parties are expected to fund up to five programs a year. Sanofi-aventis may also host postdoctoral fellows at the
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
The fingerprint technology discerns the so-called forensic ‘fingerprint’ of herbal medicine components using advanced techniques including chromatographic or spectral profiling. The profile can be used to identify different